Ganoderma lucidum ameliorates the diabetic nephropathy via down-regulatory effect on TGFß-1 and TLR-4/NFκB signalling pathways.
J Pharm Pharmacol
; 73(9): 1250-1261, 2021 Aug 12.
Article
in En
| MEDLINE
| ID: mdl-33847358
ABSTRACT
OBJECTIVES:
Diabetic nephropathy (DN) is one of the most important complications of diabetes mellitus and it is considered as a principal cause for end-stage renal failure. Ganoderma lucidum (GL) has been studied for its reno-protective effect against different kidney injury models. The aim of our study is to investigate the mechanisms by which GL can improve kidney injury and consequent renal inflammation and fibrosis.METHODS:
GL either in a low dose (250 mg/kg, i.p.) or high dose (500 mg/kg, i.p.) was administered to DN rat model, and nephropathy indices were investigated. KEYFINDINGS:
GL treatment significantly down-regulated kidney injury molecule-1 (KIM-1) gene expression and inhibited TLR-4 (Toll-like receptor-4)/NFκB (nuclear factor kappa B) signalling pathway. As well, GL treatment significantly decreased the pro-inflammatory mediator; IL-1ß (interleukin-1 beta) level and fibrosis-associated growth factors; FGF-23 (fibroblast growth factor-23) and TGFß-1 (transforming growth factor beta-1) levels. In addition, GL remarkably inhibited (Bax) the pro-apoptotic protein and induced (Bcl-2) the anti-apoptotic protein expression in kidneys. Moreover, GL treatment significantly alleviates kidney injury indicated by correcting the deteriorated kidney function and improving oxidative stress status in DN rats.CONCLUSIONS:
GL significantly improved renal function indices through dose-dependent kidney function restoration, oxidative stress reduction, down-regulation of gene expression of KIM-1 and TLR4/NFκB signalling pathway blockage with subsequent alleviation of renal inflammation and fibrosis.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
NF-kappa B
/
Reishi
/
Diabetes Mellitus, Experimental
/
Diabetic Nephropathies
/
Toll-Like Receptor 4
/
Transforming Growth Factor beta1
/
Kidney
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
J Pharm Pharmacol
Year:
2021
Document type:
Article
Affiliation country:
Egipto